Journal Article

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

Madsen, Jesper, Rasmussen, Mads F, Van Gaal, Luc, Al Hakim, Mazin, Astrup, Arne, Niskanen, Leo, Rissanen, Aila, Lean, Michael EJ, Rössner, Stephan

2009

Overview

The frequency of obesity has risen dramatically in recent years but only few safe and effective drugs are currently available. We assessed the effect of liraglutide on bodyweight and tolerability in obese individuals without type 2 diabetes. We did a double-blind, placebo-controlled 20-week trial, with open-label orlistat comparator in 19 sites in Europe. 564 individuals (18–65 years of age, body-mass index 30–40 kg/m 2) were randomly assigned, with a telephone or web-based system, to one of four liraglutide doses (1·2 mg, 1·8 mg, 2·4 mg, or 3·0 mg, n=90–95) or to placebo (n=98) administered once a day subcutaneously, or orlistat (120 mg, n=95) three times a day orally. All individuals had a 500 kcal per day energy-deficit diet and increased their physical activity throughout the trial, including the 2-week run-in. Weight change analysed by intention to treat was the primary endpoint. An 84-week open-label extension followed. This study is registered with ClinicalTrials.gov, number NCT00422058. Participants on liraglutide lost significantly more weight than did those on placebo (p=0·003 for liraglutide 1·2 mg and p<0·0001 for liraglutide 1·8–3·0 mg) and orlistat (p=0·003 for liraglutide 2·4 mg and p<0·0001 for liraglutide 3·0 mg). Mean weight loss with liraglutide 1·2–3·0 mg was 4·8 kg, 5·5 kg, 6·3 kg, and 7·2 kg compared with 2·8 kg with placebo and 4·1 kg with orlistat, and was 2·1 kg (95% CI 0·6–3·6) to 4·4 kg (2·9–6·0) greater than that with placebo. More individuals (76%, n=70) lost more than 5% weight with liraglutide 3·0 mg that with placebo (30%, n=29) or orlistat (44%, n=42). Liraglutide reduced blood pressure at all doses, and reduced the prevalence of prediabetes (84–96% reduction) with 1·8–3·0 mg per day. Nausea and vomiting occurred more often in individuals on liraglutide than in those on placebo, but adverse events were mainly transient and rarely led to discontinuation of treatment. Liraglutide treatment over 20 weeks is well tolerated, induces weight loss, improves certain obesity-related risk factors, and reduces prediabetes. Novo Nordisk A/S, Bagsvaerd, Denmark.

• Publisher: Elsevier Ltd,Elsevier,Elsevier Limited
• Subject: Analysis of Variance / Anti-Obesity Agents - therapeutic use / Biological and medical sciences / Blood pressure / Body Mass Index / Clinical medicine / Diabetes / Dose-Response Relationship, Drug / Double-Blind Method / Drug therapy / Europe - epidemiology / Female / General aspects / Glucagon-Like Peptide 1 - analogs & derivatives / Glucagon-Like Peptide 1 - pharmacology / Glucagon-Like Peptide 1 - therapeutic use / Humans / Injections, Subcutaneous / Internal Medicine / Lactones - therapeutic use / Liraglutide / Logistic Models / Male / Medical sciences / Metabolic diseases / Metabolic syndrome / Mortality / Nausea / Obesity / Obesity - complications / Obesity - drug therapy / Obesity - epidemiology / Prediabetic State - complications / Prediabetic State - prevention & control / Risk factors / Safety / Studies / Treatment Outcome / Waist Circumference - drug effects / Weight control / Weight Loss - drug effects